Bristol-Myers Squibb Company (BMY)

76.91 +1.11 (+1.46%) At close: 04:00PM EDT

Bristol-Myers Squibb Company

430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000
https://www.bms.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full Time Employees: 32,200

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Giovanni Caforio M.D.	Chairman & CEO	6.69M	N/A	1965
Mr. David V. Elkins	Exec. VP & CFO	3.24M	N/A	1968
Ms. Sandra Leung Esq.	Exec. VP & Gen. Counsel	3.03M	N/A	1961
Dr. Christopher S. Boerner	Exec. VP & Chief Commercialization Officer	2.78M	N/A	1971
Mr. Rupert Vessey BCH, BM, DPHIL, M.A.	Exec. VP and Pres of Research & Early Devel.	3.24M	1.46M	1965
Mr. Greg Meyers	Exec. VP and Chief Digital & Technology Officer	N/A	N/A	1973
Mr. Paul von Autenried	Exec. VP & Chief Information Officer	N/A	N/A	1962
Mr. Timothy Power	VP & Head of Investor Relations	N/A	N/A	N/A
Mr. Adam Dubow	Sr. VP, Chief Compliance & Ethics Officer	N/A	N/A	1967
Ms. Ann M. Powell Judge	Exec. VP & Chief HR Officer	N/A	N/A	1966

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Corporate Governance

Bristol-Myers Squibb Company’s ISS Governance QualityScore as of February 1, 2022 is 2. The pillar scores are Audit: 4; Board: 4; Shareholder Rights: 3; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.